ghk-cu tolerance downregulation desensitization long-term use effectiveness Peptide: Clinical Evidence & Injectable Protocols Exploring the beneficial effects of

[DOI] [PMC free article] [PubMed] [Google Scholar] 144.Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, Shen WJ, Kraemer FB, Bernlohr DA

What this protocol cannot promise No published human trial measures GLOW outcomes

Induction of hippocampal long-term potentiation during waking leads to increased extrahippocampal zif-268 expression during ensuing rapid-eye-movement sleep

Mean new or enlarging T2 lesions at week 72 were 0.20 in the every-6-weeks group and 0.05 in the every-4-weeks group, with a mean lesion ratio of 4.24

If the trials show efficacy that Im not expecting (the primary endpoint is the same as used for the approved beta-amyloid monoclonal antibody drugs, change in Clinical Dementia Rating Sum of Boxes score) that would be great